Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05712200
Other study ID # ANT-010
Secondary ID 2023-503224-66-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 27, 2022
Est. completion date March 2025

Study information

Verified date May 2024
Source Anthos Therapeutics, Inc.
Contact Anthos Therapeutics
Phone +1 617 430 6940
Email clinicaltrials@anthostherapeutics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 1900
Est. completion date March 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Patient is able to understand and has provided written informed consent to participate in the trial - Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording) - Age 65-74 and a CHA2DS2VASc =4 OR age =75 and a CHA2DS2VASc =3 - Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study - At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls - Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study Exclusion Criteria: - AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use) - Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF - Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment - Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization - Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study Other protocol defined Inclusion/Exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Abelacimab
Abelacimab provided as liquid in vial (150 mg/mL)
Drug:
Placebo
Dosage Formulation: Liquid (in vial) Dose Strength: Placebo to Abelacimab

Locations

Country Name City State
Brazil Anthos Investigative Site 1518 Aracaju
Brazil Anthos Investigative Site 1507 Belo Horizonte
Brazil Anthos Investigative Site 1516 Belo Horizonte
Brazil Anthos Investigative Site 1527 Belo Horizonte
Brazil Anthos Investigative Site 1528 Belo Horizonte
Brazil Anthos Investigative Site 1505 Blumenau
Brazil Anthos Investigative Site 1513 Blumenau
Brazil Anthos Investigative Site 1535 Brasília
Brazil Anthos Investigative Site 1501 Campina Grande Do Sul
Brazil Anthos Investigative Site 1503 Campinas
Brazil Anthos Investigative Site 1522 Campinas
Brazil Anthos Investigative Site 1520 Campo Grande
Brazil Anthos Investigative Site 1532 Canoas
Brazil Anthos Investigative Site 1526 Caxias Do Sul
Brazil Anthos Investigative Site 1509 Curitiba
Brazil Anthos Investigative Site 1540 Curitiba
Brazil Anthos Investigative Site 1525 Goiânia
Brazil Anthos Investigative Site 1502 Marília
Brazil Anthos Investigative Site 1533 Passo Fundo
Brazil Anthos Investigative Site 1506 Porto Alegre
Brazil Anthos Investigative Site 1508 Porto Alegre
Brazil Anthos Investigative Site 1517 Porto Alegre
Brazil Anthos Investigative Site 1519 Porto Alegre
Brazil Anthos Investigative Site 1524 Porto Alegre
Brazil Anthos Investigative Site 1530 Porto Alegre
Brazil Anthos Investigative Site 1531 Recife
Brazil Anthos Investigative Site 1515 Ribeirão Preto
Brazil Anthos Investigative Site 1536 Ribeirão Preto
Brazil Anthos Investigative Site 1537 Rio De Janeiro
Brazil Anthos Investigative Site 1510 Salvador
Brazil Anthos Investigative Site 1521 Salvador
Brazil Anthos Investigative Site 1529 São Paulo
Brazil Anthos Investigative Site 1534 São Paulo
Brazil Anthos Investigative Site 1514 Tatuí
Brazil Anthos Investigative Site 1504 Votuporanga
Bulgaria Anthos Investigative Site 6014 Blagoevgrad
Bulgaria Anthos Investigative Site 6026 Burgas
Bulgaria Anthos Investigative Site 6019 Gabrovo
Bulgaria Anthos Investigative Site 6018 Haskovo
Bulgaria Anthos Investigative Site 6013 Panagyurishte
Bulgaria Anthos Investigative Site 6025 Pazardzhik
Bulgaria Anthos Investigative Site 6003 Pleven
Bulgaria Anthos Investigative Site 6006 Pleven
Bulgaria Anthos Investigative Site 6004 Plovdiv
Bulgaria Anthos Investigative Site 6007 Plovdiv
Bulgaria Anthos Investigative Site 6008 Plovdiv
Bulgaria Anthos Investigative Site 6009 Plovdiv
Bulgaria Anthos Investigative Site 6021 Plovdiv
Bulgaria Anthos Investigative Site 6027 Sliven
Bulgaria Anthos Investigative Site 6022 Smolyan
Bulgaria Anthos Investigative Site 6001 Sofia
Bulgaria Anthos Investigative Site 6002 Sofia
Bulgaria Anthos Investigative Site 6010 Sofia
Bulgaria Anthos Investigative Site 6012 Sofia
Bulgaria Anthos Investigative Site 6015 Sofia
Bulgaria Anthos Investigative Site 6017 Sofia
Bulgaria Anthos Investigative Site 6020 Sofia
Bulgaria Anthos Investigative Site 6023 Sofia
Bulgaria Anthos Investigative Site 6024 Sofia
Bulgaria Anthos Investigative Site 6028 Sofia
Bulgaria Anthos Investigative Site 6011 Stara Zagora
Canada Anthos Investigative Site 2016 Abbotsford
Canada Anthos Investigative Site 2003 Cambridge Ontario
Canada Anthos Investigative Site 2007 Chicoutimi Quebec
Canada Anthos Investigative Site 2015 Edmonton
Canada Anthos Investigative Site 2005 Halifax
Canada Anthos Investigative Site 2012 Mira Road Nova Scotia
Canada Anthos Investigative Site 2014 Montréal
Canada Anthos Investigative Site 2004 New Westminster
Canada Anthos Investigative Site 2021 North Vancouver
Canada Anthos Investigative Site 2002 Québec
Canada Anthos Investigative Site 2006 Saint-Jérôme
Canada Anthos Investigative Site 2010 Sherbrooke Quebec
Canada Anthos Investigative Site 2022 Thunder Bay
Chile Anthos Investigative Site 1606 Independencia
Chile Anthos Investigative Site 1604 Providencia
Chile Anthos Investigative Site 1607 San Bernardo
Chile Anthos Investigative Site 1609 San Miguel
Chile Anthos Investigative Site 1608 Santiago
Chile Anthos Investigative Site 1610 Talcahuano
Chile Anthos Investigative Site 1602 Temuco
Chile Anthos Investigative Site 1603 Temuco
Chile Anthos Investigative Site 1601 Viña Del Mar
China Anthos Investigative Site 1818 Changchun
China Anthos Investigative Site 1810 Changsha
China Anthos Investigative Site 1811 Changsha
China Anthos Investigative Site 1802 Chengdu
China Anthos Investigative Site 1809 Haidian
China Anthos Investigative Site 1801 Hangzhou
China Anthos Investigative Site 1808 Hangzhou
China Anthos Investigative Site 1816 Jinan
China Anthos Investigative Site 1804 Lianyungang
China Anthos Investigative Site 1814 Luoyang
China Anthos Investigative Site 1817 Nanchang
China Anthos Investigative Site 1820 Nanchang
China Anthos Investigative Site 1803 Nanjing
China Anthos Investigative Site 1815 Ningbo
China Anthos Investigative Site 1819 Shijiazhuang
China Anthos Investigative Site 1812 Tianjin
China Anthos Investigative Site 1813 Yangzhou
China Anthos Investigative Site 1805 Yinchuan
Czechia Anthos Investigative Site 3002 Brandýs Nad Labem
Czechia Anthos Investigative Site 3006 Liberec
Czechia Anthos Investigative Site 3007 Ostrava - Poruba
Czechia Anthos Investigative Site 3001 Podebrady
Czechia Anthos Investigative Site 3003 Prague
Czechia Anthos Investigative Site 3004 Praha
Czechia Anthos Investigative Site 3005 Praha
Czechia Anthos Investigative Site 3010 Praha
Czechia Anthos Investigative Site 3009 Trutnov
Germany Anthos Investigative Site 7006 Altenburg
Germany Anthos Investigative Site 7014 Berlin
Germany Anthos Investigative Site 7004 Dresden
Germany Anthos Investigative Site 7003 Hamburg
Germany Anthos Investigative Site 7013 Hannover
Germany Anthos Investigative Site 7002 Markkleeberg
Germany Anthos Investigative Site 7007 Paderborn
Germany Anthos Investigative Site 7001 Schwerin
Hungary Anthos Investigative Site 4002 Békéscsaba
Hungary Anthos Investigative Site 4006 Budapest
Hungary Anthos Investigative Site 4009 Budapest
Hungary Anthos Investigative Site 4015 Budapest
Hungary Anthos Investigative Site 4011 Gyöngyös
Hungary Anthos Investigative Site 4012 Kaposvar
Hungary Anthos Investigative Site 4007 Kistarcsa
Hungary Anthos Investigative Site 4005 Nyíregyháza
Hungary Anthos Investigative Site 4010 Pécs
Hungary Anthos Investigative Site 4017 Szeged
Hungary Anthos Investigative Site 4016 Veszprém
Hungary Anthos Investigative Site 4008 Zalaegerszeg
India Anthos Investigative Site 2310 Ahmedabad
India Anthos Investigative Site 2314 Kolkata
India Anthos Investigative Site 2315 Nagpur
India Anthos Investigative Site 2316 Nagpur
India Anthos Investigative Site 2317 Pune
India Anthos Investigative Site 2309 Secunderabad
India Anthos Investigative Site 2312 Visakhapatnam
Israel Anthos Investigative Site 1210 Afula
Israel Anthos Investigative Site 1205 Ashkelon
Israel Anthos Investigative Site 1209 H_olon
Israel Anthos Investigative Site 1206 Hadera
Israel Anthos Investigative Site 1201 Haifa
Israel Anthos Investigative Site 1211 Haifa
Israel Anthos Investigative Site 1204 Kfar Saba
Israel Anthos Investigative Site 1202 Nahariya
Israel Anthos Investigative Site 1207 Petah tikva
Israel Anthos Investigative Site 1203 Re?ovot
Israel Anthos Investigative Site 1208 Zefat
Italy Anthos Investigative Site 8003 Bologna
Italy Anthos Investigative Site 8008 Catanzaro
Italy Anthos Investigative Site 8007 Milan
Italy Anthos Investigative Site 8001 Milano
Italy Anthos Investigative Site 8002 Roma
Italy Anthos Investigative Site 8010 Roma
Italy Anthos Investigative Site 8011 Roma
Italy Anthos Investigative Site 8004 Saronno
Italy Anthos Investigative Site 8005 Sesto San Giovanni
Italy Anthos Investigative Site 8014 Torino
Italy Anthos Investigative Site 8006 Varese
Italy Anthos Investigative Site 8009 Vittoria
Japan Anthos Investigative Site 1908 Chikushino-shi
Japan Anthos Investigative Site 1902 Chuo-Ku
Japan Anthos Investigative Site 1920 Funabashi-Shi
Japan Anthos Investigative Site 1910 Hamada-shi
Japan Anthos Investigative Site 1906 Himeji-Shi
Japan Anthos Investigative Site 1911 Imabari-shi
Japan Anthos Investigative Site 1912 Isehara-Shi
Japan Anthos Investigative Site 1921 Koto-Ku
Japan Anthos Investigative Site 1915 Kure-shi
Japan Anthos Investigative Site 1903 Matsumoto-Shi
Japan Anthos Investigative Site 1907 Nagano-Shi
Japan Anthos Investigative Site 1922 Sapporo-shi
Japan Anthos Investigative Site 1904 Sendai-shi
Japan Anthos Investigative Site 1913 Shimonoseki-shi
Japan Anthos Investigative Site 1914 Tachikawa-shi
Japan Anthos Investigative Site 1909 Tochigi
Japan Anthos Investigative Site 1901 Urayasu
Japan Anthos Investigative Site 1917 Uwajima-Shi
Japan Anthos Investigative Site 1916 Yokohama-Shi
Japan Anthos Investigative Site 1918 Yokohama-shi
Japan Anthos Investigative Site 1919 Yokohama-Shi
Latvia Anthos Investigative Site 2103 Baldone
Latvia Anthos Investigative Site 2109 Balvi
Latvia Anthos Investigative Site 2107 Daugavpils
Latvia Anthos Investigative Site 2108 Limbazi
Latvia Anthos Investigative Site 2101 Riga
Latvia Anthos Investigative Site 2102 Riga
Latvia Anthos Investigative Site 2105 Riga
Latvia Anthos Investigative Site 2110 Riga
Latvia Anthos Investigative Site 2111 Sigulda
Latvia Anthos Investigative Site 2104 Valmiera
Latvia Anthos Investigative Site 2106 Valmiera
Mexico Anthos Investigative Site 1701 Aguascalientes
Mexico Anthos Investigative Site 1707 Aguascalientes
Mexico Anthos Investigative Site 1713 Aguascalientes
Mexico Anthos Investigative Site 1721 Chihuahua
Mexico Anthos Investigative Site 1703 Culiacán
Mexico Anthos Investigative Site 1704 Monterrey
Mexico Anthos Investigative Site 1702 Querétaro
Mexico Anthos Investigative Site 1718 San Luis Potosí
Mexico Anthos Investigative Site 1706 Veracruz
Mexico Anthos Investigative Site 1708 Veracruz
Poland Anthos Investigative Site 5022 Czeladz
Poland Anthos Investigative Site 5003 Katowice
Poland Anthos Investigative Site 5005 Katowice
Poland Anthos Investigative Site 5009 Katowice
Poland Anthos Investigative Site 5016 Kraków
Poland Anthos Investigative Site 5018 Kraków
Poland Anthos Investigative Site 5012 Lódz
Poland Anthos Investigative Site 5028 Lódz
Poland Anthos Investigative Site 5006 Lublin
Poland Anthos Investigative Site 5023 Lublin
Poland Anthos Investigative Site 5008 Olsztyn
Poland Anthos Investigative Site 5025 Oswiecim
Poland Anthos Investigative Site 5002 Przemysl
Poland Anthos Investigative Site 5004 Rzeszów
Poland Anthos Investigative Site 5001 Tychy
Poland Anthos Investigative Site 5011 Warszawa
Poland Anthos Investigative Site 5014 Warszawa
Poland Anthos Investigative Site 5015 Warszawa
Poland Anthos Investigative Site 5017 Warszawa
Poland Anthos Investigative Site 5007 Wroclaw
Poland Anthos Investigative Site 5019 Wroclaw
Romania Anthos Investigative Site 9022 Balotesti
Romania Anthos Investigative Site 9001 Braila
Romania Anthos Investigative Site 9023 Bucharest
Romania Anthos Investigative Site 9019 Bucuresti
Romania Anthos Investigative Site 9024 Cluj-Napoca
Romania Anthos Investigative Site 9006 Craiova
Romania Anthos Investigative Site 9017 Craiova
Romania Anthos Investigative Site 9010 Oradea
Romania Anthos Investigative Site 9014 Pitesti
Romania Anthos Investigative Site 9025 Pitesti
Romania Anthos Investigative Site 9012 Satu Mare
Romania Anthos Investigative Site 9003 Târgu-Mures
Romania Anthos Investigative Site 9004 Târgu-Mures
Romania Anthos Investigative Site 9016 Târgu-Mures
Romania Anthos Investigative Site 9021 Târgu-Mures
Romania Anthos Investigative Site 9005 Timisoara
Romania Anthos Investigative Site 9007 Timisoara
Romania Anthos Investigative Site 9008 Timisoara
Romania Anthos Investigative Site 9013 Timisoara
Romania Anthos Investigative Site 9018 Timisoara
Spain Anthos Investigative Site 1108 A Coruña
Spain Anthos Investigative Site 1116 Almería
Spain Anthos Investigative Site 1109 Cabra
Spain Anthos Investigative Site 1103 Granada
Spain Anthos Investigative Site 1111 Jaén
Spain Anthos Investigative Site 1118 León
Spain Anthos Investigative Site 1104 Madrid
Spain Anthos Investigative Site 1106 Madrid
Spain Anthos Investigative Site 1113 Madrid
Spain Anthos Investigative Site 1117 Madrid
Spain Anthos Investigative Site 1105 Málaga
Spain Anthos Investigative Site 1110 Murcia
Spain Anthos Investigative Site 1115 Oviedo
Spain Anthos Investigative Site 1107 Santiago De Compostela
Spain Anthos Investigative Site 1102 Sevilla
Spain Anthos Investigative Site 1112 Terrassa
Spain Anthos Investigative Site 1101 Valencia
Spain Anthos Investigative Site 1119 Vigo
United Kingdom Anthos Investigative Site 1303 Corby
United Kingdom Anthos Investigative Site 1315 Hayle
United Kingdom Anthos Investigative Site 1311 High Wycombe
United Kingdom Anthos Investigative Site 1301 Isleworth
United Kingdom Anthos Investigative Site 1309 Leeds
United Kingdom Anthos Investigative Site 1308 London
United Kingdom Anthos Investigative Site 1314 London
United Kingdom Anthos Investigative Site 1312 Manchester
United Kingdom Anthos Investigative Site 1307 Newcastle Upon Tyne
United Kingdom Anthos Investigative Site 1305 Peterborough
United Kingdom Anthos Investigative Site 1302 Stevenage
United Kingdom Anthos Investigative Site 1310 Stockton-on-Tees
United Kingdom Anthos Investigative Site 1306 Taunton
United States Anthos Investigative Site 1006 Alexandria Louisiana
United States Anthos Investigative Site 1084 American Fork Utah
United States Anthos Investigative Site 1039 Baltimore Maryland
United States Anthos Investigative Site 1054 Bangor Maine
United States Anthos Investigative Site 1040 Birmingham Alabama
United States Anthos Investigative Site 1013 Boca Raton Florida
United States Anthos Investigative Site 1082 Boston Massachusetts
United States Anthos Investigative Site 1031 Bountiful Utah
United States Anthos Investigative Site 1074 Bristol Pennsylvania
United States Anthos Investigative Site 1065 Cary North Carolina
United States Anthos Investigative Site 1005 Charlotte North Carolina
United States Anthos Investigative Site 1022 Clearwater Florida
United States Anthos Investigative Site 1025 Clearwater Florida
United States Anthos Investigative Site 1019 Daytona Beach Florida
United States Anthos Investigative Site 1049 Denver Colorado
United States Anthos Investigative Site 1091 El Paso Texas
United States Anthos Investigative Site 1050 Elizabethton Tennessee
United States Anthos Investigative Site 1018 Falls Church Virginia
United States Anthos Investigative Site 1048 Fayetteville North Carolina
United States Anthos Investigative Site 1057 Germantown Tennessee
United States Anthos Investigative Site 1089 Gilbert Arizona
United States Anthos Investigative Site 1035 Henderson North Carolina
United States Anthos Investigative Site 1029 Holladay Utah
United States Anthos Investigative Site 1083 Hollywood Florida
United States Anthos Investigative Site 1087 Horsham Pennsylvania
United States Anthos Investigative Site 1053 Houston Texas
United States Anthos Investigative Site 1064 Houston Texas
United States Anthos Investigative Site 1068 Houston Texas
United States Anthos Investigative Site 1069 Houston Texas
United States Anthos Investigative Site 1008 Jacksonville Florida
United States Anthos Investigative Site 1080 Kansas City Missouri
United States Anthos Investigative Site 1023 Lanham Maryland
United States Anthos Investigative Site 1021 Lansing Michigan
United States Anthos Investigative Site 1036 Las Vegas Nevada
United States Anthos Investigative Site 1001 Lenoir North Carolina
United States Anthos Investigative Site 1066 Lincoln Nebraska
United States Anthos Investigative Site 1052 Lithonia Georgia
United States Anthos Investigative Site 1078 Loma Linda California
United States Anthos Investigative Site 1077 Los Angeles California
United States Anthos Investigative Site 1093 Lutz Florida
United States Anthos Investigative Site 1033 Macon Georgia
United States Anthos Investigative Site 1010 Manassas Virginia
United States Anthos Investigative Site 1063 McAllen Texas
United States Anthos Investigative Site 1079 McKinney Texas
United States Anthos Investigative Site 1056 Memphis Tennessee
United States Anthos Investigative Site 1072 Miami Lakes Florida
United States Anthos Investigative Site 1014 Middletown New York
United States Anthos Investigative Site 1041 Mobile Alabama
United States Anthos Investigative Site 1042 Norcross Georgia
United States Anthos Investigative Site 1015 Northridge California
United States Anthos Investigative Site 1024 Odessa Texas
United States Anthos Investigative Site 1067 Ormond Beach Florida
United States Anthos Investigative Site 1030 Park Ridge Illinois
United States Anthos Investigative Site 1038 Pleasant View Utah
United States Anthos Investigative Site 1085 Port Arthur Texas
United States Anthos Investigative Site 1070 Redding California
United States Anthos Investigative Site 1009 Roanoke Virginia
United States Anthos Investigative Site 1032 Rock Hill South Carolina
United States Anthos Investigative Site 1028 Rockville Maryland
United States Anthos Investigative Site 1037 Rosedale New York
United States Anthos Investigative Site 1034 Roy Utah
United States Anthos Investigative Site 1026 Safety Harbor Florida
United States Anthos Investigative Site 1002 Saint Augustine Florida
United States Anthos Investigative Site 1004 Saint Augustine Florida
United States Anthos Investigative Site 1071 San Dimas California
United States Anthos Investigative Site 1076 Santa Ana California
United States Anthos Investigative Site 1043 Shreveport Louisiana
United States Anthos Investigative Site 1059 Southgate Michigan
United States Anthos Investigative Site 1012 Stamford Connecticut
United States Anthos Investigative Site 1090 Sugar Land Texas
United States Anthos Investigative Site 1003 Suwanee Georgia
United States Anthos Investigative Site 1073 Tacoma Washington
United States Anthos Investigative Site 1044 Tamarac Florida
United States Anthos Investigative Site 1088 Tamarac Florida
United States Anthos Investigative Site 1046 Tampa Florida
United States Anthos Investigative Site 1011 Tomball Texas
United States Anthos Investigative Site 1017 Tupelo Mississippi
United States Anthos Investigative Site 1060 Waco Texas
United States Anthos Investigative Site 1016 Wichita Kansas
United States Anthos Investigative Site 1092 Wylie Texas

Sponsors (1)

Lead Sponsor Collaborator
Anthos Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Brazil,  Bulgaria,  Canada,  Chile,  China,  Czechia,  Germany,  Hungary,  India,  Israel,  Italy,  Japan,  Latvia,  Mexico,  Poland,  Romania,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy: Time to first event of ischemic stroke or systemic embolism (SE) Up to 30 months
Primary Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding Up to 30 months
Secondary Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia Abelacimab versus placebo with regard to the composite of ischemic stroke, SE, MI, VTE, or acute limb ischemia Up to 30 months
Secondary Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event Up to 30 months
Secondary Efficacy: Cardiovascular (CV) mortality Up to 30 months
Secondary Efficacy: All-cause mortality Up to 30 months
Secondary Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding Abelacimab versus placebo with regard to net clinical outcome defined as the composite of ischemic stroke, SE, MI, VTE, acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding Up to 30 months
See also
  Status Clinical Trial Phase
Completed NCT02630914 - Medical and Surgical Hybrid Treatment of Atrial Fibrillation. N/A
Completed NCT05410379 - Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
Enrolling by invitation NCT05407415 - KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation N/A
Completed NCT04025710 - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep) N/A
Completed NCT01119274 - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Phase 4
Recruiting NCT03428048 - Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
Recruiting NCT04298723 - Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding. N/A
Completed NCT04218266 - Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. Phase 2
Active, not recruiting NCT03732794 - AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment N/A
Active, not recruiting NCT04755283 - Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Phase 2
Completed NCT04095559 - Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
Recruiting NCT05955365 - Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation Phase 4
Recruiting NCT05294445 - From the Emergency Department Directly to Ablation of Atrial Fibrillation Study N/A
Completed NCT02513316 - Clinical Relevance of Microbleeds In Stroke N/A
Completed NCT04809922 - Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation